Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Equity: 2020-2024

Historic Return on Equity for Silence Therapeutics (SLN) over the last 5 years, with Dec 2024 value amounting to 0.58%.

  • Silence Therapeutics' Return on Equity was N/A to 0.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77%, marking a year-over-year change of. This contributed to the annual value of 0.58% for FY2024, which is 162.00% up from last year.
  • Silence Therapeutics' Return on Equity amounted to 0.58% in FY2024, which was up 73.64% from 2.20% recorded in FY2023.
  • Silence Therapeutics' Return on Equity's 5-year high stood at 0.58% during FY2024, with a 5-year trough of 4.64% in FY2021.
  • Moreover, its 3-year median value for Return on Equity was 2.20% (2023), whereas its average is 1.94%.
  • Its Return on Equity has fluctuated over the past 5 years, first tumbled by 246bps in 2021, then soared by 162bps in 2024.
  • Silence Therapeutics' Return on Equity (MRY) stood at 2.18% in 2020, then crashed by 113bps to 4.64% in 2021, then skyrocketed by 34bps to 3.05% in 2022, then increased by 28bps to 2.20% in 2023, then skyrocketed by 74bps to 0.58% in 2024.
  • Its Return on Equity stands at 0.58% for FY2024, versus 2.20% for FY2023 and 3.05% for FY2022.